国际医药卫生导报
國際醫藥衛生導報
국제의약위생도보
INTERNATIONAL MEDICINE & HEALTH GUIDANCE NEWS
2013年
19期
3013-3016
,共4页
耿玉六%李安%张保友%王腾飞
耿玉六%李安%張保友%王騰飛
경옥륙%리안%장보우%왕등비
胸腔镜%肺叶切除术%非小细胞肺癌
胸腔鏡%肺葉切除術%非小細胞肺癌
흉강경%폐협절제술%비소세포폐암
Thoracoscopic%Pulmonary lobectomy%Non-small-cell lung cancer
目的 分析胸腔镜肺叶切除术治疗原发性非小细胞肺癌的临床价值和安全性.方法 将我院2010年5月至2013年2月收治的60例原发性非小细胞肺癌患者随机分为观察组(n=30)和对照组(n=30),观察组患者采用胸腔镜肺叶切除术治疗,对照组患者采用常规开胸肺叶切除术治疗,然后分析两组患者的疗效和安全性.结果 观察组患者的手术时间、术中出血量、术后引流量、住院时间和并发症率都显著小于对照组患者(P<0.05),但是两组患者的淋巴结清扫数目差异无统计学意义(P>0.05).结论 胸腔镜肺叶切除术治疗非小细胞肺癌具有安全、创伤小、恢复快、并发症少等优势,可以作为治疗非小细胞肺癌的首选方法.
目的 分析胸腔鏡肺葉切除術治療原髮性非小細胞肺癌的臨床價值和安全性.方法 將我院2010年5月至2013年2月收治的60例原髮性非小細胞肺癌患者隨機分為觀察組(n=30)和對照組(n=30),觀察組患者採用胸腔鏡肺葉切除術治療,對照組患者採用常規開胸肺葉切除術治療,然後分析兩組患者的療效和安全性.結果 觀察組患者的手術時間、術中齣血量、術後引流量、住院時間和併髮癥率都顯著小于對照組患者(P<0.05),但是兩組患者的淋巴結清掃數目差異無統計學意義(P>0.05).結論 胸腔鏡肺葉切除術治療非小細胞肺癌具有安全、創傷小、恢複快、併髮癥少等優勢,可以作為治療非小細胞肺癌的首選方法.
목적 분석흉강경폐협절제술치료원발성비소세포폐암적림상개치화안전성.방법 장아원2010년5월지2013년2월수치적60례원발성비소세포폐암환자수궤분위관찰조(n=30)화대조조(n=30),관찰조환자채용흉강경폐협절제술치료,대조조환자채용상규개흉폐협절제술치료,연후분석량조환자적료효화안전성.결과 관찰조환자적수술시간、술중출혈량、술후인류량、주원시간화병발증솔도현저소우대조조환자(P<0.05),단시량조환자적림파결청소수목차이무통계학의의(P>0.05).결론 흉강경폐협절제술치료비소세포폐암구유안전、창상소、회복쾌、병발증소등우세,가이작위치료비소세포폐암적수선방법.
Objective To analyze effect and safety of thoracoscopic pulmonary lobectomy in the treatment of primary non-small-cell lung cancer.Methods 60 patients with primary non-small-cell lung cancer in our hospital from May 2010 to February 2013 were randomly divided into observation group (n=30) and control group (n=30).Observation group was given thoracoscopic pulmonary lobectomy,while control group was given open thoracotomy.Then analyzed the effect and safety of two groups.Results The operation time,intraoperative blood loss,postoperative suction drainage,hospitalization time,and rate of complications in observation group were significantly lower than those in control group (P < 0.05).However,there was no significant difference in the number of dissected lymph node between two groups (P > 0.05).Conclusions Thoracoscopic pulmonary lobectomy in the treatment of non-small-cell lung cancer has many advantages,such as safety,minimal invasion,quick recovery,and few complications,which can be preferred method for non-small-cell lung cancer.